Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Lupus nephritis
•
Cyclophosphamide
•
Scleroderma
•
SLE
When do you consider Mesna for patients taking oral cyclophosphamide?
What dose do you use? Do you utilize oral or IV infusion Mesna?
Related Questions
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How would you approach a patient with newly diagnosed lupus/lupus nephritis receiving cyclophosphamide (euro lupus protocol) with active hemolysis not responding to steroids or IVIG?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
What Barrett's Esophagus screening protocol do you follow for patients with scleroderma given the increased risk of reflux and esophageal stasis?
How do you interpret a negative ANCA and a low positive PR3?
How would you approach a patient with SLE and stage 4 LN who presents with persistent significant elevation in ESR, CRP and dsDNA despite improvement of symptoms and resolution of proteinuria on MMF and HCQ?
Do you always pursue biopsy confirmation before diagnosing IgA vasculitis?
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
